TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20151341

Group type: EXPERIMENTAL
Intervention: Topical lidocaine 40 mg followed by propofol 2 mg.kg(‐1) (Group 2PL; n = 30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol 3 mg.kg(‐1) (Group 3P; n = 30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Propofol 2 mg.kg(‐1) (Group 2P; n = 30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol 3 mg.kg(‐1) (Group 3P)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Propofol 2 mg.kg(‐1) (Group 2P)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Topical lidocaine 40 mg followed by propofol 2 mg.kg(‐1) (Group 2PL)
Number of subjects: 90
Study: 19140507

Group type: EXPERIMENTAL
Intervention: Combined therapy with enalapril and prolonged-release verapamil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined therapy with enalapril and moxonidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril monotherapy
Number of subjects: 0
Study: 15179690

Group type: EXPERIMENTAL
Intervention: Finasteride pretreatment for 7 to 14 days before TURP
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Finasteride pretreatment
Number of subjects: 80
Study: 11113797

Group type: EXPERIMENTAL
Intervention: 400 mg of ibuprofen taken orally 1 hour before separator placement
Number of subjects: 63

Group type: COMPARATOR
Intervention: 400 mg of ibuprofen taken orally immediately after separator placement
Number of subjects: 63

Group type: COMPARATOR
Intervention: Lactose placebo taken orally 1 hour before separator placement and again immediately after the appointment
Number of subjects: 63
Study: 9340476

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study: 8336583

Group type: EXPERIMENTAL
Intervention: Continuous daily regimen of 0.3 mg CEE and one of three low-dose progestogens (medroxyprogesterone acetate 2.5 mg, levonorgestrel 30 micrograms or norethisterone 350 micrograms)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Continuous daily regimen of 0.3 mg CEE and one of three low-dose progestogens
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Norethisterone therapy
Number of subjects: 75
Study: 3013566

Group type: EXPERIMENTAL
Intervention: sulbactam/ampicillin
Number of subjects: 39

Group type: COMPARATOR
Intervention: metronidazole/gentamicin
Number of subjects: 39
Study: 30113643

Group type: EXPERIMENTAL
Intervention: Pedestrian training program focusing on where to cross (n=44)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Pedestrian training program focusing on how to cross safely (n=43)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (video game, n=22 for where to cross, n=21 for how to cross)
Number of subjects: 130
Study: 27375972

Group type: EXPERIMENTAL
Intervention: Reciproc (R)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Hand instrumentation (H)
Number of subjects: 137
Study: 25033717

Group type: EXPERIMENTAL
Intervention: Vaginal intercourse at least twice a week
Number of subjects: 123

Group type: COMPARATOR
Intervention: Abstinence (control group)
Number of subjects: 123
Study: 22490809

Group type: EXPERIMENTAL
Intervention: Clinical pathway (CP) for etiological diagnosis of acute biliary pancreatitis
Number of subjects: 2216

Group type: COMPARATOR
Intervention: Control group (standard methods)
Number of subjects: 2216

Group type: EXPERIMENTAL
Intervention: CP group
Number of subjects: 2216
Study: 19703096

Group type: EXPERIMENTAL
Intervention: FearNot! intervention
Number of subjects: 1129
Study: 18506512

Group type: EXPERIMENTAL
Intervention: Bilateral PEMF treatment (n = 14)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Bilateral sham devices (n = 14)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: One breast with active device and one with sham device (n = 14)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Postoperative analgesic medication use
Number of subjects: 42
Study: 16170233

Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg in experiments 1 and 3; 150 mg in experiment 2)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Caffeine deprivation state
Number of subjects: 68
Study: 12544035

Group type: EXPERIMENTAL
Intervention: Zinc 50 mg daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo pill containing starch
Number of subjects: 41
Study: 10857888

Group type: EXPERIMENTAL
Intervention: Arm A: three 8-mg doses of ondansetron IV at 4-hour intervals plus dexamethasone 20 mg IV from the start of chemotherapy followed by dexamethasone 5 mg IV every 12 hours.
Number of subjects: 275

Group type: COMPARATOR
Intervention: Arm B: three 8-mg doses of ondansetron IV at 24-hour intervals plus dexamethasone 20 mg IV from the start of chemotherapy followed by dexamethasone 5 mg IV every 12 hours.
Number of subjects: 275

Group type: COMPARATOR
Intervention: Arm A and Arm B (comparison of dosing intervals).
Number of subjects: 275
Study: 8645590

Group type: EXPERIMENTAL
Intervention: Women attending the family history clinic and participating in the Tamoxifen Prevention Trial
Number of subjects: 186

Group type: COMPARATOR
Intervention: Women not attending any specialist clinic (NBSP)
Number of subjects: 186
Study: 1512162

Group type: EXPERIMENTAL
Intervention: Cranial irradiation, 24 Gy and i.t. MTX 10 mg/m2, 6 doses (RT group)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: i.t. Ara‐C 30 mg/m2 and i.t. MTX 10 mg/m2, 10 doses (ChT group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (Siblings, Sb)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (Solid Tumors, ST)
Number of subjects: 54
Study: 6391073

Group type: EXPERIMENTAL
Intervention: One-session laser trabeculoplasty
Number of subjects: 77

Group type: COMPARATOR
Intervention: Two-session laser trabeculoplasty
Number of subjects: 77
Study: 30526261

Group type: EXPERIMENTAL
Intervention: Graston Technique® (GT)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Self‐myofascial release (SMR)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both GT and SMR
Number of subjects: 26
Study: 30549358

Group type: EXPERIMENTAL
Intervention: Concurrent cetuximab plus docetaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30035825

Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 516

Group type: COMPARATOR
Intervention: Voriconazole
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Possible IMD
Number of subjects: 516

Group type: COMPARATOR
Intervention: Proven/probable IMD
Number of subjects: 516
Study: 26493812

Group type: EXPERIMENTAL
Intervention: Calcium carbonate 1 g/day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (no calcium)
Number of subjects: 41
Study: 24507221

Group type: EXPERIMENTAL
Intervention: Tailored training for GPs based on qualitative research findings with focus groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 22030802

Group type: EXPERIMENTAL
Intervention: Oxygen uptake efficiency plateau (OUEP) during cardiopulmonary exercise testing (CPET)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: OUEP combined with oscillatory breathing
Number of subjects: 508

Group type: COMPARATOR
Intervention: Other resting or exercise parameters
Number of subjects: 508
Study: 19845414

Group type: EXPERIMENTAL
Intervention: Brief interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy for symptomatic management (anxiety or insomnia)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0
Study: 17203013

Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg, oral) in pathological gamblers
Number of subjects: 38

Group type: COMPARATOR
Intervention: Haloperidol (3 mg, oral) in non-gambler controls
Number of subjects: 38
Study: 15008861

Group type: EXPERIMENTAL
Intervention: BBL + BTX-A
Number of subjects: 30

Group type: COMPARATOR
Intervention: BBL alone
Number of subjects: 30
Study: 11913308

Group type: EXPERIMENTAL
Intervention: Baking Soda Chewing Gum
Number of subjects: 85

Group type: COMPARATOR
Intervention: Breath Mint Placebo
Number of subjects: 85
Study: 9336527

Group type: EXPERIMENTAL
Intervention: Noncemented total hip prostheses
Number of subjects: 226

Group type: COMPARATOR
Intervention: Cemented total hip prostheses
Number of subjects: 226
Study: 7950475

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 3602942

Group type: EXPERIMENTAL
Intervention: Acetyl salicylic acid (3 g daily for one week)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg daily for one week)
Number of subjects: 6
Study: 29233548

Group type: EXPERIMENTAL
Intervention: Actual weight-based (AWB) chemotherapy dosing
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Underweight/normal weight BMI subgroup
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: BSA 25th-50th percentile
Number of subjects: 615

Group type: COMPARATOR
Intervention: BMI categories
Number of subjects: 615
Study: 26899254

Group type: EXPERIMENTAL
Intervention: Medical writing support
Number of subjects: 233

Group type: COMPARATOR
Intervention: No medical writing support
Number of subjects: 233
Study: 24279429

Group type: EXPERIMENTAL
Intervention: Mortality salience (writing about death)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aversive control topic (writing about a non-death topic)
Number of subjects: 0
Study: 22554311

Group type: EXPERIMENTAL
Intervention: Fomepizole IV or orally (7 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral loading doses of 10‐15 mg/kg, followed by supplemental doses of 3‐10 mg/kg/12 h through 96 hours
Number of subjects: 0
Study: 20861293

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg at night
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 17588821

Group type: EXPERIMENTAL
Intervention: OP-1 Putty
Number of subjects: 36

Group type: COMPARATOR
Intervention: Autogenous iliac crest bone graft
Number of subjects: 36
Study: 16000995

Group type: COMPARATOR
Intervention: International guidelines single-sample estimates of GFR
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: New equation derived from the data
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Slope-intercept method described in the BNMS guidelines
Number of subjects: 425
Study: 14597346

Group type: EXPERIMENTAL
Intervention: HIFU followed by mastectomy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (mastectomy)
Number of subjects: 48
Study: 12851773

Group type: EXPERIMENTAL
Intervention: Tolterodine extended-release 4 mg once daily
Number of subjects: 410
Study: 10425569

Group type: EXPERIMENTAL
Intervention: Crohn's disease activity index
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Laboratory variables (erythrocyte sedimentation rate, chloraemia, serum albumin)
Number of subjects: 110
Study: 7781461

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 276

Group type: COMPARATOR
Intervention: Ranitidine 300 mg
Number of subjects: 276
Study: 2114429

Group type: EXPERIMENTAL
Intervention: Orem's Self-Care Deficit Nursing Theory
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control unit (standard nursing care)
Number of subjects: 0
Study: 362518

Group type: EXPERIMENTAL
Intervention: Sulbenicillin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Carbenicillin
Number of subjects: 16
Study: 31590569

Group type: EXPERIMENTAL
Intervention: Six-minute walk test
Number of subjects: 60

Group type: COMPARATOR
Intervention: Educational control condition
Number of subjects: 60
Study: 27999024

Group type: EXPERIMENTAL
Intervention: ceftolozane/tazobactam
Number of subjects: 94

Group type: COMPARATOR
Intervention: meropenem
Number of subjects: 94

Group type: COMPARATOR
Intervention: levofloxacin
Number of subjects: 94
Study: 25297064

Group type: EXPERIMENTAL
Intervention: EF (3.0 g/L oligofructose)
Number of subjects: 95

Group type: COMPARATOR
Intervention: CF (α-lactalbumin-enriched control formula)
Number of subjects: 95
Study: 23360899

Group type: EXPERIMENTAL
Intervention: 66 vol.% nitrous oxide (N2O)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 21288228

Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil bolus (0.4 μg/kg) administered immediately after a contraction trigger
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil bolus (0.4 μg/kg) administered 140 seconds before the next contraction
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Delayed boluses in a subgroup with long and regular contractions
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 50
Study: 19262478

Group type: EXPERIMENTAL
Intervention: Aliskiren alone or in combination with a diuretic or a calcium channel blocker (CCB)
Number of subjects: 345
Study: 16902750

Group type: EXPERIMENTAL
Intervention: Virtual reality simulator training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanical robotic training
Number of subjects: 0
Study: 15692716

Group type: EXPERIMENTAL
Intervention: Partial carbon dioxide rebreathing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thermodilution
Number of subjects: 20
Study: 11709518

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg four times daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 9358913

Group type: EXPERIMENTAL
Intervention: Asbestos-exposed individuals
Number of subjects: 292

Group type: COMPARATOR
Intervention: Nonexposed heavy smokers
Number of subjects: 292
Study: 7962879

Group type: EXPERIMENTAL
Intervention: Random-effects regression model for clustered data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ordinary regression analysis of clustered data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classroom-level analysis
Number of subjects: 0
Study: 3668983

Group type: EXPERIMENTAL
Intervention: Colchicine 1.5 mg daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31524498

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study: 27902645

Group type: EXPERIMENTAL
Intervention: Nerve Stimulation (NS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ultrasound (US)
Number of subjects: 80
Study: 25376434

Group type: EXPERIMENTAL
Intervention: Preoperative inspiratory muscular training (IMT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 44
Study: 23480238

Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk (PFM) containing Bifidobacterium lactis CNCM I-2494
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk (PFM)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control dairy product
Number of subjects: 324
Study: 21664867

Group type: EXPERIMENTAL
Intervention: Combination of bevacizumab (10 mg/kg every 2 weeks) and temsirolimus (25 mg weekly; group A)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Sunitinib (50 mg/day for 4 weeks followed by 2 weeks off; group B)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Combination of interferon alfa (9 mIU three times per week) and bevacizumab (10 mg/kg every 2 weeks; group C)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Combination of bevacizumab and temsirolimus (group A)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Sunitinib (group B)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Combination of interferon alfa and bevacizumab (group C)
Number of subjects: 171
Study: 19835123

Group type: EXPERIMENTAL
Intervention: Inhibitory-needling method (INM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine-needling method (RNM)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 17537152

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg day(-1))
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 14982784

Group type: EXPERIMENTAL
Intervention: Indinavir every 8 h (n = 8)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Indinavir 1000 mg every 12 h with nelfinavir (n = 10)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Indinavir 1200 mg every 12 h with nelfinavir (n = 7)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Indinavir with nelfinavir (combined data)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nelfinavir (in combination with indinavir 1000 mg every 12 h) (n = 9)
Number of subjects: 25
Study: 11133744

Group type: EXPERIMENTAL
Intervention: Liposomal ATRA (90 mg/m(2) every other day until complete remission or a maximum of 56 days)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Liposomal ATRA
Number of subjects: 69
Study: 9468068

Group type: EXPERIMENTAL
Intervention: Accelerated alteplase
Number of subjects: 40747

Group type: COMPARATOR
Intervention: Streptokinase or combination therapy
Number of subjects: 40747

Group type: EXPERIMENTAL
Intervention: Patients with prior myocardial infarction
Number of subjects: 40747

Group type: COMPARATOR
Intervention: Patients without prior myocardial infarction
Number of subjects: 40747
Study: 7865956

Group type: EXPERIMENTAL
Intervention: En bloc extended radical mastectomy (EXT)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional radical mastectomy (RDL)
Number of subjects: 118
Study: 2464777

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 60
Study: 773601

Group type: EXPERIMENTAL
Intervention: Methacycline 600 mg daily for 14 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ampicillin 2 gm daily for 14 days
Number of subjects: 20
Study: 31764258

Group type: COMPARATOR
Intervention: Placebo products (crossover study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tablets, ring, and injections (TRIO study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaginal products (ring, insert, film, and gel) (Quatro study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discrete choice experiment
Number of subjects: 0
Study: 27319277

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 102

Group type: COMPARATOR
Intervention: Intravenous ibuprofen
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both oral and intravenous ibuprofen
Number of subjects: 102
Study: 25222105

Group type: EXPERIMENTAL
Intervention: Intensive low‐GL intervention
Number of subjects: 95

Group type: COMPARATOR
Intervention: General dietary intervention (Control group)
Number of subjects: 95
Study: 24338756

Group type: EXPERIMENTAL
Intervention: Cap Assisted Colonoscopy (CAC)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Conventional Colonoscopy (CC)
Number of subjects: 504
Study: 22052276

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using 20% 5‐aminolevulinic acid solution (ALA) and blue light
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ALA with blue light
Number of subjects: 15

Group type: COMPARATOR
Intervention: ALA vehicle and blue light
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using ALA with blue light
Number of subjects: 15
Study: 18632591

Group type: EXPERIMENTAL
Intervention: Automated eGFR reporting and clinician education
Number of subjects: 1019
Study: 17215967

Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion
Number of subjects: 93

Group type: COMPARATOR
Intervention: Glucometer-guided insulin injection
Number of subjects: 93
Study: 12966017

Group type: EXPERIMENTAL
Intervention: Counselling and a safety kit including preventive devices and pamphlets about indoor injuries (Group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Counselling only (Group 2)
Number of subjects: 100
Study: 10849057

Group type: EXPERIMENTAL
Intervention: RACM regimen (rabeprazole 10 mg bid, amoxicillin 750 mg bid, clarithromycin 200 mg bid, metronidazole 250 mg bid)
Number of subjects: 105

Group type: COMPARATOR
Intervention: RAC regimen (rabeprazole 10 mg bid, amoxicillin 750 mg bid, clarithromycin 200 mg bid)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: RACM regimen
Number of subjects: 105

Group type: COMPARATOR
Intervention: RAC regimen
Number of subjects: 105
Study: 9107431

Group type: EXPERIMENTAL
Intervention: 125 mg of oltipraz daily
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: 500 mg of oltipraz weekly
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 8260183

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Both radiotherapy and cyclophosphamide
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Both radiotherapy and tamoxifen
Number of subjects: 1153

Group type: COMPARATOR
Intervention: No radiotherapy
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Local treatment only
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Combination of surgery, radiotherapy and hormone therapy
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Aggressive local treatment with hormone therapy
Number of subjects: 1153
Study: 3535975

Group type: EXPERIMENTAL
Intervention: Clovoxamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxepin
Number of subjects: 0
Study: 30845920

Group type: EXPERIMENTAL
Intervention: CELC (vitamin C, vitamin E, lysozyme, and carbazochrome)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29397594

Group type: EXPERIMENTAL
Intervention: Combined group C (live combined Bacillus subtilis and Enterococcus)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (routine treatment with polyene phosphatidylcholine capsules)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Combined groups (A, B, C)
Number of subjects: 200
Study: 27509606

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous administration of lipoic acid (0.6 g) and alprostadil (10 mg)
Number of subjects: 60
Study: 25392671

Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic pyeloplasty
Number of subjects: 112

Group type: COMPARATOR
Intervention: Retroperitoneoscopic laparoscopic pyeloplasty
Number of subjects: 112